INTERIM FINANCIAL STATEMENTS FOR THE SECOND QUARTER ENDED 30 JUNE 2020
"Expansion of cold chain distribution facilities, essential for vaccine distribution, has been completed in Singapore and will be completed by the fourth quarter in Malaysia."
Capacity Increase for Cold Chain Vaccine Distribution In addition, the Group also reported that expansion of its cold chain distribution facilities, essential for vaccine distribution, has been completed in Singapore and will be completed by the fourth quarter of 2020 in Malaysia. “For many years now, we have been supplying a wide range of vaccines and biologicals under cold chain distribution specifications directly to many healthcare professionals in Malaysia and Singapore. The planned capacity increase is timely as volume is growing. We will also be ready to play our role in the supply chain when vaccines for COVID-19 become available” added Dr Kee
Just a myth. Contrary to popular belief, pharmaceutical companies like ApexH are also faced with an uncertain outlook for 2H2020 due to disruptions caused by the pandemic. Weaker consumer sentiment and cautious spending has impacted ApexH’s sales, while the deferment elective medical procedures like orthopaedic surgeries has resulted in lower demand for Straits Apex’s orthopaedic devices. However, during this tough time, ApexH has also completed its cold chain distribution expansion in Singapore, while the expansion in Malaysia is expected to complete in 4QFY20. Given that cold chain distribution is vital for the distribution of vaccine, we are positive on this timely expansion as ApexH would be able to expand into vaccine distribution, be it a Covid-19 vaccine or other vaccines available. However, contrary to market’s belief, we are not expecting immediate benefit arising from any potential vaccine distribution by Apex Source: PublicInvest Research - 27 Aug 2020
Sinopharm Vaccine (linked to Kanger) is on track for full approval in November or December
“The most promising of these, developed by Wuhan-based Sinopharm, is already being given to frontline workers in the United Arab Emirates. According to Wu Guizhen, chief biosafety expert at the Chinese Center for Disease Control and Prevention, Sinopharm’s candidate is on track for full approval this month or next.”
Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy.
-----------
US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said.
Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released.
The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said.
Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.
But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive."
Sinovac vaccine is not related to any companies in Malaysia but just wanted to share anyway.
------------ Brazilian politics, US pressure likely behind Chinese vaccine's suspension: experts
The Chinese Foreign Ministry, the Chinese vaccine producer and a Brazilian institute clarified that Brazilian health regulator's decision to halt trials of a Chinese-produced COVID-19 vaccine in Brazil is NOT RELATED TO THE VACCINE ITSELF, after foreign media said the suspension came following a "severe adverse event."
Chinese experts said politicization of vaccine issues by some Brazilian politicians was likely the reason. They said the vaccine trial issue, which is life-saving work amid the COVID-19 pandemic, should not be influenced by Brazilian political disputes or US pressure.
They stressed that the vaccine is essential to fight the virus, but the suspension without a reasonable excuse could slow down the vaccine-development process.
Wang Wenbin, spokesperson of the ministry, said at a press conference on Tuesday we notice that BUTANTAN INSTITUTE, partner of China's Sinovac Biotech in Brazil, has concluded that the reported "adverse event" that caused Brazil's health regulator on Monday to suspend trials of a Chinese-produced vaccine in Brazil was NOT RELATED TO THE VACCINE produced by Sinovac.
People jump to vaccine company. Do we realise without supply chain and logistics also problem? Apex play important roles and has facilities and temperature control in distributing the vaccine.
China National Pharmaceutical Group Corp (SINOPHARM), a Chinese state-owned enterprise, announced on Wednesday that data from late-stage clinical trials for its Covid-19 vaccine are «BETTER THAN EXPECTED», Reuters reported.
In Morocco, Dr. Abdelhakim Yahyane, a member of the National Scientific Advisory Committee on Vaccination, told Yabiladi earier this week that vaccine trials in the country «have REACHED THE FINAL PHASE».
We are impatiently awaiting the end of this process, which could probably happen BY NEXT WEEK
If moderna vaccine is for real, apex health can play a substantial role. Apparently, moderna's vaccine requires storage of only -20C. This is exactly what apex health has, storage facilities that meet this requirement. Hopefully, such important information is not lost on the public. This counter has great potential
Eventually vaccine makers will need to come to Apex Healthcare for its cold chain facility which will be completed in Q4. It just completed it’s cold chain in Singapore. Perfect stock for the recovery trend
profit seems to have recovered back to pre covid level. next to see is after they completed their cold chain network, whehter they are able to secure distribution contract for the vaccine.
On 14th September, the Group’s wholly owned manufacturing subsidiary Xepa-Soul Pattinson (M) Sdn Bhd secured renewal of its GMP status with the National Pharmaceutical Regulatory Authority (‘NPRA’) through a scheduled desktop audit. In the quarter, Apex Pharma Marketing Pte Ltd in Singapore increased its cold chain distribution capabilities with the expansion of its current 2-8 degrees C cold room and the acquisition of a -20 degrees C freezer room for pharmaceuticals, vaccines and biologics. Expansion of cold chain distribution capacity in Malaysia is scheduled for completion before the end of the current financial year. Review of Year To Date Performance versus Corresponding Period Last Year
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
sour_grape_so_sour
40 posts
Posted by sour_grape_so_sour > 2020-08-12 07:38 | Report Abuse
actually ubat also down since last week.....it it the liquidity draining away